Skip to content

Usefulness of Homoeopathy in the management of Obsessive Compulsive Disorder

The effectiveness of Individualized Homoeopathic Medicines in LM potencies in reducing the symptoms of Obsessive Compulsive Disorder: An Open Label Clinical Study - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/01/061060
Enrollment
35
Registered
2024-01-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F42- Obsessive-compulsive disorder

Interventions

Intervention1: Individualized Homoeopathic Medicines in LM potencies: After enrolment the indicated medicine shall be prescribed in LM potency starting with 0/1 as water dose. Mode of administration o

Sponsors

Dr. Liza K B
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cases satisfying OCD diagnostic criteria of DSM 5 with Y-BOCS total score equal or above 8.

Exclusion criteria

Exclusion criteria: 1. OCD with other psychotic comorbidity 2. Other substance or medication induced OCD 3. Subjects undergoing any other treatment mode including psychotherapy for OCD 4. Pregnant or lactating mothers 5. Subjects unwilling to give consent form

Design outcomes

Primary

MeasureTime frame
To find out the changes in the symptoms of Obsessive Compulsive Disorder assessed by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) using Individualized Homoeopathic Medicines in LM potencies.Timepoint: Every third month from baseline till end of study (12th month)

Secondary

MeasureTime frame
The changes in quality of life will be assessed using WHOQOL-BREFTimepoint: Baseline and at end of the study (12th month)

Countries

India

Contacts

Public ContactDr S Karunakara Moorthi

National Homoeopathy Research Institute in Mental Health

drjaiguru@gmail.com8281502571

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026